Abbott Labs' Upcoming FDA Audit Is Final Hurdle Of Consent Decree
This article was originally published in The Gray Sheet
Executive Summary
An FDA inspection of Abbott Labs' Lake County, Illinois diagnostics manufacturing facility, anticipated in late August or early September, will last two to four weeks, the firm predicts.
You may also be interested in...
Abbott's AFP, CA 125 Cancer Tests Unaffected By Consent Decree
Abbott Laboratories' AFP and CA 125 diagnostic cancer tests are among the diagnostic products deemed "medically necessary" by FDA and will continue to be made available under the company's Nov. 2 consent decree with the agency.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.